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Background: Previous research has shown that electro-acupuncture (EA) may be effective for functional
constipation. We report a protocol for a randomized controlled trial using EA to confirm the efficacy and safety for
severe chronic functional constipation.
Methods/design: This is a randomized, controlled trial. A total of 1,034 patients will be randomly allocated into the
EA group (n=517) and the sham EA group (n=517). The EA group receives needling at ST25, SP14 and ST37 and the
sham EA group receives needling at sham ST25, SP14 and ST37. The primary outcome measure is the changed
number of weekly average complete spontaneous bowel movements(CSBMs) during 8 weeks of treatment,
compared with baseline. The secondary outcome measures are: 1) the proportion of participants having three or
more CSBMs on average per week; 2) the changed number of weekly average CSBMs during weeks 9 to 20; 3) the
changed number of weekly average spontaneous bowel movements during 8 weeks of treatment; 4) stool
consistency; 5) degree of difficulty in defecation; 6) patient assessment of constipation quality of life questionnaire
(PAC-QOL); 7) incidence of adverse events; and 8) usage of medicine for constipation.
Discussion: This trial will evaluate the efficacy and safety of EA for severe chronic functional constipation.
Trial registration: Protocol Registration System of ClinicalTrial.gov, NCT01726504
Keywords: Chronic functional constipation, Electro-acupuncture, Multicenter RCT, Efficacy, SafetyBackground
Constipation is a common gastrointestinal disease. Re-
cent data showthat the incidence of chronic functional
constipation is 14.7% in the USA [1] and 11.6% in Asia
[2]. Despite an instant effect, long-term use of western
medicine usually results in drug dependence, melanosis
coli, laxative constipation or even canerization [3]. To
date, there are hardly any specific therapies for chronic
functional constipation. Systematic reviews indicate that* Correspondence: baoyan.liu.cacms@gmail.com
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reproduction in any medium, provided the oracupuncture is probably effective for the disease, which
maybe better than western medicine, but the evidence is
limited [4]. Our pilot study showed deep needling
electro-acupuncture (EA) worked from week 1, which
was quicker than either shallow needling (worked from
week 2) or medication with lactulose (Duphalac) [5,6].
The treatment group adopted deep needling at ST25, who
showed a frequency of weekly defecation of 2.75±1.48,
compared with the shallow needling group (0.79±0.93)
and the medication group (2.17±1.15) after 4 weeks of
treatment. This study indicated that deep needling EA at
ST25 might be superior to shallow puncture and
Duphalac, but further research is needed to provide more
evidence.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Design
This is a randomized, controlled, two-arm, large-scale
trial comparing EA with sham EA (Figure 1). Guang An
Men Hospital of China Academy of Chinese Medical Sci-
ences is the investigative hospital, and 1,034 patients will
be included from the following fifteen hospitals: Guang
An Men Hospital of China Academy of Chinese Medical
Sciences (South Branch); West China Hospital of Sichuan
University; Guangdong Hospital of Traditional Chinese
Medicine (TCM); Heilongjiang Institute of TCM; Beijing
Hospital of TCM; Huguosi TCM Hospital of Beijing Uni-
versity of TCM; 1st Affiliated Hospital of Tianjin Univer-
sity of TCM; Dongzhimen Hospital of Beijing University
of TCM; 3rd Affiliated Hospital of Zhejiang University of
TCM; 301 Hospital; Wuhan Hospital of Integrated TCM
and Western Medicine; Yueyang Hospital of Shanghai Uni-
versity of TCM; Nanjing University of TCM; Jiangsu Hos-
pital of TCM; Anhui Hospital of TCM. All acupuncture
manipulators are required to have an official license and in-
dividual clinical work experience lasting more than 2 years.
The participants will be allocated through central
randomization in a 1:1 ratio. The central randomizationFigure 1 Flow diagram of study design.will be performed by the Clinical Evaluation Center at
the China Academy of Chinese Medical Sciences. A ran-
dom number and group assignment will be immediately
received by telephone, mobile phone, or website sent
from the central randomization system.
The duration of this study is 22 weeks for each partici-
pant. All participants are asked to record constipation
diaries from 2 weeks before randomization for the base-
line data. If they are eligible for this trial, they will be
asked to continue the diaries, recording from weeks 1 to
20 after randomization.
Participants will receive 28 sessions of EA or sham EA
over 8 weeks, with a treatment frequency of five times
per week in the first 2 weeks, and three times per week
for the following 6 weeks. Each session will lasts for 30
minutes. The follow-up period is 12 weeks (weeks 9 to
20 after randomization).Patients
Study population
This study will include patients with severe chronic func-
tional constipation (n=1034). To ensure the precision of
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bility criteria.
Inclusion criteria
Participants will be included if they fulfil the following
conditions: meeting the diagnosis of Rome III criteria [7]
for chronic functional constipation; severe chronic con-
stipation (two or fewer complete spontaneous bowel
movements (CSBMs) per week for more than 3 months;
aged 18 to 75 years old; no use of medicine for constipa-
tion during the 2 weeks before enrollment (except res-
cue medication usage which is defined as follow: if
participants do not have a bowel movement for three or
more consecutive days during the trial, they were per-
mitted to take 110 ml Glycerol Enema, H11022362110,
Beijing Maidihai Medical Co. Ltd, Beijing, China; 110
ml/bottle); no acupuncture treatment for constipation in
the previous 3 months; never joined any other trial in
progress in the previous 3 months; volunteered to join
this research and signed the informed consent.
Exclusion criteria
Patients with any of the following conditions will be ex-
cluded: irritable bowel syndrome and secondary consti-
pation caused by endocrine, metabolic, nervous or
postoperative diseases or drugs; constipation accompan-
ied by serious cardiovascular, hepatic, renal, or psychi-
atric diseases, cognitive dysfunction or aphasia, or severe
dystrophy affecting the cooperation for examination or
treatment; pregnant women or women in lactation; consti-
pation accompanied by abdominal aneurysm, hepato-
splenomegaly, etcetera; bleeding disorders, or regular
anticoagulant drug users, such as warfarin and heparin,
etcetera; cardiac pacemaker carrier.
Recruitment procedures
Participants will be recruited by newspaper, television,
internet propaganda (http://www.gamhospital.ac.cn/) and
posters in the community and hospitals (both TCM hos-
pital and western medicine hospital). Prospective partici-
pants will be asked to talk face to face with the study
coordinator to discuss the study and provide information
regarding eligibility criteria. If the patient is eligible and in-
terested in participating, they will be invited for a baseline
screening visit after diagnosis by the doctor of the anus-
intestines department or the gastroenterology department.
Ethical considerations
This trial has been approved by all fifteen local ethics
committees (September 6, 2012) including: Guang An
Men Hospital of China Academy of Chinese Medical
Sciences (South Branch); West China Hospital of Sichuan
University; Guangdong Hospital of TCM; Heilongjiang In-
stitute of TCM; Beijing Hospital of TCM; Huguosi TCMHospital of Beijing University of TCM; 1st Affiliated Hos-
pital of Tianjin University of TCM; Dongzhimen Hospital
of Beijing University of TCM; 3rd Affiliated Hospital of
Zhejiang University of TCM; 301 Hospital; Wuhan Hos-
pital of Integrated TCM and Western Medicine; Yueyang
Hospital of Shanghai University of TCM; Nanjing Univer-
sity of TCM; Jiangsu Hospital of TCM; Anhui Hospital of
TCM. The trial follows the principles of the Declaration of
Helsinki (Version Edinburgh 2000). Before the ran-
domization, all patients will be requested to sign a written
informed consent; meanwhile, they will be given enough
time to decide whether they are willing to participate in
this trial, or choose other treatment options.
Randomization
A central stratified block randomization will be designed
for this study by the central randomization system with
a 1:1 allocation ratio. Stratified randomization will be
made in terms of center. The randomization protocol
and related index are produced by professional biostatis-
ticians with SAS 9.3 software, procedure PROC PLAN
(SAS software (Beijing) Co., Ltd, Office 1801-1803, E1
building, Dongfang Square, No. 1 Changan Road,
Dongcheng District, Beijing, China, 100738). Related
content such as the setting parameters will be saved with
the blind codes. The randomization will be conducted
by a central randomization system (telephone version
and internet version). If a volunteer meets the inclusion
criteria, the appointed center researcher will apply for
the randomized number.
The randomization protocol will be designed by a stat-
istician of the China Academy of Chinese Medical Sci-
ence who will not be involved in the later statistical
work of this project.
Blind codes mean the randomization protocol and the
parameters are set during the procedure. The ran-
domization protocol designer will seal these files and
sign them. The sealed files will be deposited by an
appointed member of staff who will not take part in this
project. Central randomization has strict limits of au-




The acupuncture points are Tianshu (ST25), Fujie
(SP14), Shangjuxu (ST37) (Additional file 1: Picture 1).
After sterilizing the skin, filiform needles are inserted
3 to 8 cm into bilateral ST25 and SP14 vertically and
slowly without any manipulation until touching the par-
ietal peritoneum. The standard for reaching the parietal
peritoneum is that the participant feels sharp pain again
(after the first pain of piercing the skin) and, meanwhile,
the manipulator feels resistance from the needle tip. An
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Suzhou, China) is applied to bilateral ST25 and SP14
with a dilatational wave of 10/50 Hz and electric current
between 0.1 and 1.0 mA. The participant's abdominal
muscle twitching mildly indicates the appropriate dose.
The bilateral ST37 is inserted 3cm - twirling, lifting and
thrusting three times. A local sour and heavy feeling in-
dicates the appropriate dose. Steady small twirling,
lifting and thrusting manipulation will be used three
times in each session.
Each session will last for 30 minutes per day. The par-
ticipants are treated continuously for 8 weeks. During
the first 2 weeks, five sessions will be given per week,
and three sessions per week in the remaining 6 weeks.
There are 28 sessions for each patient in total.
Control group
The acupuncture points aresham Tianshu (ST25), sham
Fujie (SP14), sham Shangjuxu (ST37) (Additional file 2:
Picture 2).
Sham location points are: about 2cm away from ST25,
in the middle of the spleen and stomach channel; about
3 cm from SP14, in the middle of the spleen and stom-
ach channel; one point beside ST37, in the middle of
the stomach and gallbladder channel (Additional file 2:
Picture 2).
The needle is inserted after sterilizing the skin by 1 to
1.5 cm, until the needle can be vertically fixed on the
skin. No twirling lifting and thrusting manipulation is
used. The sham electric stimulator (sham SDZ-V EA ap-
paratus; Huatuo) is applied to the bilateral sham ST25 and
sham SP14 with a dilatational wave of 10/50 Hz and elec-
tric current of 0.5 mA. The metal wire has been cut off in-
side to give the appearance of the real electric stimulator,
with no current output. Length of treatment and the treat-
ment sessions are the same as the treatment group.
Rescue medication
During the 2 weeks of screening and 12 weeks of follow-
up, patients are asked to avoid any other treatments
after 8 weeks of acupuncture treatment. An emergency
treatment is permitted if participants do not have a
bowel movement for three or more consecutive days
during the trial -they are allowed to take 110 ml Gly-
cerol Enema (Glycerol Enema, H11022362110, Beijing
Maidihai Medical Co. Ltd; 110 ml/bottle) as rescue
medication, which is provided by the investigators. Every
use of Glycerol Enema should be recorded in the diary.
And any other concomitant medications should also be
recorded in the diary.
Outcome measurement
The main endpoint is the weekly frequency of CSBMs,
measured every week from weeks 1 to 20.Primary outcome measures
The primary outcome of the study is the changed num-
ber of weekly average CSBMs during 8 weeks treatment
compared with baseline.
Secondary outcome measures
The secondary outcome measures include the following
eight items: 1) the proportion of participants having
three or more CSBMs on average per week during the
20 weeks measured at the end of weeks 8 and 20 after
randomization; 2) the changed number of weekly aver-
age spontaneous bowel movements (SBMs) during the 8
weeks of treatment measured at the end week 8; 3) stool
consistency measured every week during the 8 weeks of
treatment; 4) degree of difficulty in defecation measured
every week during the 8 weeks of treatment; 5) patient
assessment ofconstipationquality of life questionnaire
(PAC-QOL) measured at the end of week 8 after
randomization; 6) incidence of adverse events during the
8 weeks of treatmentmeasured at the end of week 8; 7)
incidence of adverse events; 8) usage of medicine for
constipation - any medicine for constipation used during
the trial will be recorded, as well as the dosage and
amount of every drug.
The participantis asked to keep a stool diary every day
for 22 weeks, from 2 weeks before randomization to the
end of week 20 after randomization. The content in-
cludes the SBM, CSBM, the stool consistency, degree of
difficulty in defecation, the usage of drugs, diet, etcetera.
The diaries will be collected once a week during the first
10 weeks, and every 4 weeks during the last 12 weeks.
All adverse events happening during the trial will be
recorded, such as local hematoma, breaking of needle,
retained needle after treatment, fainting, unbearable
prickling, and continuous severe pain more than 1hour
after acupuncture, local infection and abscess, etcetera.
Serious adverse events should be reported to the princi-
pal investigator immediately.
Quality control
To guarantee the quality of the study, the trial protocol is
reviewed and revised by experts of acupuncture, gastro-
enterology, statistics, and methodology several times. A
central randomization system is adopted to avoid selection
bias. Strict eligible criteria are pre-set to restrict the
research population. Blinded effect assessment and
blinded statistics are designed to guarantee the objec-
tivity of the data. All research staff, especially the acu-
puncture manipulators,are required to attend a series
of training. The training courses include how to use
the central randomization system, how to fill the case
report form, how to manipulate interventions cor-
rectly, how to teach the patients to fulfil the diary,
how to assess the effect, etcetera. A inspection plan is
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will check the 15 sub-centers regularly and finish
paper which will be reported to the principal investi-
gator. The first level is sub-center monitor, who
appointed by the head of the sub-center; the second
level is investigative hospital monitor, who appointed
by Guang An Men Hosptila; the third level is the
Quality Control Group monitor, who appointed by
Evaluation Center of China Academy of Chinese Medical
Scinece. Methods for improving compliance are also
considered, such as traffic compensation, heath education,
etcetera. A Data and Safety Monitoring Board (DSMB)
was set up on 22 June 2012 to monitor the performance
and safety of the trial, which is composed mainly of
experts from different fields on the Chinese mainland.
Sample size calculation and statistical analysis
According to our previous study, the weekly CSBM in-
crease was conservatively estimatedat 1.49 times, with a
standard deviation of 1.77, after 8 weeks EA treatment;
the weekly CSBMs increased by 1.01, with a standard
deviation of 1.61, after 8 weeks sham EA treatment. We
used SAS 9.3 to define the 95% power, using a one-way
analysis of variance fixed effects omnibus test, assuming
a 20% loss to follow-up. To ensure the stratified ran-
domization, the sample size calculation result is 1,034.
As the main objective is to compare the changed num-
ber of weekly average CSBMs throughout the 8 weeks of
treatment with the average weekly CSBMs during the 2
weeks baseline period, the primary analysis of the
patient-level data is the number of CSBMs per week for
8 weeks. It means the total amount of CSBMs during 8
weeks will be divided by eight to achieve the result.
(Each patient therefore has one number of weekly
CSBMs throughout the 8 weeks of treatment). A simple
way is to calculate the average number of CSBMs per
week over 8 weeks for each patient and use non-
parametric Wilcoxon statistics to test the null hypothesis
that this number of CSBMs is the same between the EA
and sham EA groups, with the alternative hypothesis
that the change from baseline in CSBMs at 8weeks for
the EA group does not equal the sham EA group. All pa-
tients at randomization are included in the analysis set
regardless of whether they receive any treatment.
According to the intent-to-treat principle, all analysis is
based on the randomization analysis set. To account for
correlation due to repeated measurements and to assess
the dependence of the treatment effect on time, we will
also use a random-effect Poisson regression model to
compare the effect of EA versus sham EA on our pri-
mary outcome. If the distribution of the change from
baseline in CSBMs at 8 weeks is a normal distribution,
analysis of covariance (ANCOVA) will be used, and if
the distribution is not a normal distribution, non-parametric analysis methods will be used. Study site and
baseline will be included in the ANCOVA model as a
covariant.
The secondary outcome measures include the follow-
ing eight items: 1) the proportion of participants having
three or more CSBMs on average per week; 2) the
changed number of weekly average CSBMs during weeks
9 to 20; 3) the changed number of weekly average SBMs
during the 8 weeks of treatment; 4) stool consistency; 5)
degree of difficulty in defecation; 6) PAC-QOL; 7) inci-
dence of adverse events; 8) usage of medicine for consti-
pation. The stool consistency is classified into seven
categories according to the Bristol Stool Scale [8]. A ran-
dom effect ordinal regression model will be used to
compare the difference in the stool consistency between
the EA and sham EA groups. A random effect general-
ized linear model will be used to compare the difference
in PAC-QOL between the EA and sham EA groups. All
adverse events and serious adverse events will be listed.
Random effect Poisson models will be used to compare
the incidence of adverse events between the EA and
sham EA groups. In addition, the usage of medicine for
constipation will be compared between the two groups.
The subjects who donot receive any treatment after
randomization or receive treatment but not any efficacy
assessment data are classed as missing data, and an in-
verse probability weighting method will be used for mul-
tiple imputation to deal with the missing data.
Subgroup analysis will be conducted according to the
subject’s age (<65 years and ≥65 years). In order to as-
sess the central effect, the interaction effect of the study
site and group will be tested.
A Fisher Exact test will be used to describe the case
distribution in the EA group and the sham EA group
and to calculate the total drop-out rate and the drop-out
rate caused by adverse events between the two groups.
Analysis of baseline characteristics will analyze the
demographic data and other baseline measures. Mean
and standard deviation will be used in the continuous
variables an percentages in the categorical variables. For
comparisons the two independent sample, t-test will be
used for continuous variables and Chi-squared test for
categorical variables. Non-parametric tests may also be
used. A Chi-square test is used to analyze the difference
in compliance between the two groups,to evaluate if the
participants in the EA group and the sham EA group re-
ceive the specified treatment according to the protocol.
All statistical analyses will be two-sided tests. For all
statistical analyses, SAS 9.1.3/SPSS Ver.13.0 software will
be used. A P value of less than 0.05 (α-value of 0.05) is
considered to indicate statistical significance. Mean and
standard deviation will be used in the continuous vari-
ables and percentages in the categorical variables. For
comparisons, the two independent sample t-test will be
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test for categorical variables. Non-parametric tests will
be used for variables which do not follow a normal
distribution.
Discussion
Functional constipation is one of the 43 common dis-
eases for which acupuncture treatment is recommended
by the World Health Organization [9]. Our earlier study
showed that EA might be effective for functional consti-
pation. Severe chronic functional constipation reduces
the patients’ quality of life and causes some complica-
tions [10]. Medicine could increase the frequency of
CSMBs and improve the quality of life, but it shows a
short-term effect, which will mostly disappear after dis-
continuing medication and may give rise to side effects
[11]. Our previous research indicated that EA is effective
for functional constipation, especially having a post-
treatment effect, but the result is insufficient to explain
whether there was placebo effect. As the sample size was
small, the superiority of EA for constipation could not
be demonstrated clearly. This trial is designed to explore
a standardized effective acupuncture method for severe
chronic functional constipation and assess its efficacy
and safety.
This study is supported by the 12th National Key
Technology Support Program (No. 2012BAI24B01) which
gives further financial support for functional constipation
following the 11th National Key Technology Support Pro-
gram. This trial is a multicenter, centrally randomized,
controlled study which is large in scale (n=1034). Thus,
quality control is considered as very important,as we de-
scribed in the protocol.
To ensure the efficacy, we choose sham EA as a pla-
cebo. Some papers have reported that acupuncture has
no significant differencescompared to sham acupuncture
[12-14]. To confirm the efficacy of EA for severe chronic
functional constipation, we chose a commonly used
sham method as described in western journals as the
control group - superficial insertion at non-acupuncture
points [15] with no current output using an EA simula-
tor. We used an EA apparatus which has the metal wire
removed, giving an identical visual appearance to the
real one. The electric stimulator looks normal but has
no current output. This method helps with patient
blinding, which should eliminate the placebo effect of
EA as far as possible. Therefore, the results of this study
could provide evidence to confirm the efficacy of EA for
severe chronic functional constipation.
We must emphasize the choice of the main endpoint.
Weekly frequency of CSBMs is the primary endpoint,
which is considered to be clinically meaningful since it
combines a subjective measure of the completeness of
evacuation with an objective measure of the number ofbowel movements and reflects the relief of chronic con-
stipation [3].
This trial is also designed to observe the post-
treatment effect of acupuncture during the follow-up
period in weeks 4, 8 and 12 after treatment. The time
this effect lasts for could indicate the effective superior-
ity of EA. The secondary endpoint is the changed num-
ber of weekly average CSBMs during the follow-up
stage, which could complement the comprehensive ef-
fects of acupuncture.
To ensure the quality and safety of our trial, a DSMB
was set up which is composed mainly of experts from
different fields in China. A DSMB secretariat was set up
to service the board. All the DSMB experts have signed
the ‘DSMB Consultant Agreement’ and participate in
the regular meetings according to the DSMB Charter.
Up to December 2012, two DSMB regular meetings
have been held.
Conclusion
This trial is expected to confirm that EA is effective and
safe for severe functional constipation.
Trial status
The first participants were included on 8 October 2012
and this article was submitted on 24 January 2013. To
date, 285 participants have been recruited.
Additional files
Additional file 1: The acupuncture points of Acupuncture group.
Additional file 2: The acupuncture points of Control group.
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